journal article·2022-11Open access

Transcript Engineered Extracellular Vesicles Alleviate Alloreactive Dynamics in Renal Transplantation

Jinwen Lin, Junhao Lv, Shiping Yu, Ying Chen, Huiping Wang, Jianghua Chen

Advanced Science· Volume 9· Issue 31

Abstract

Abstract Direct contact of membrane molecules and cytokine interactions orchestrate immune homeostasis. However, overcoming the threshold of distance and velocity barriers, and achieving adhesion mediated immune interaction remain difficult. Here, inspired by the natural chemotaxis of regulatory T cells, multifunctionalized FOXP3 genetic engineered extracellular vesicles, termed Foe‐TEVs, are designed, which display with adhesive molecules, regulatory cytokines, and coinhibitory contact molecules involving CTLA‐4 and PD‐1, by limited exogenous gene transduction. Foe‐TEVs effectively adhere to the tubular, endothelial, and glomerular regions of allogeneic injury in the renal allograft, mitigating cell death in situ and chronic fibrosis transition. Remarkably, transcript engineering reverses the tracking velocity of vesicles to a retained phenotype and enhanced arrest coefficient by a factor of 2.16, directly interacting and attenuating excessive allosensitization kinetics in adaptive lymphoid organs. In murine allogeneic transplantation, immune adhesive Foe‐TEVs alleviate pathological responses, restore renal function with well ordered ultrastructure and improved glomerular filtration rate, and prolong the survival period of the recipient from 30.16 to 92.81 days, demonstrating that the delivery of extracellular vesicles, genetically engineered for immune adhesive, is a promising strategy for the treatment of graft rejection.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Extracellular vesicles in disease · Reproductive System and Pregnancy · Complement system in diseases

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Kidney Disease Center The First Affiliated Hospital Zhejiang University School of Medicine Key Laboratory of Kidney Disease Prevention and Control Technology National Key Clinical Department of Kidney Diseases Institute of Nephrology Zhejiang University, and Zhejiang Clinical Research Center of Kidney and Urinary System Disease Hangzhou Zhejiang Province 310003 P. R. China

Zhejiang University‐University of Edinburgh Institute School of Medicine Zhejiang University Hangzhou Zhejiang Province 310003 P. R. China

Funding

National Natural Science Foundation of China

References (62)

Show source-provided references
1. 10.1038/nri186410.1038/nri1864 ↗
2. 10.1146/annurev-immunol-042718-04144710.1146/annurev-immunol-042718-041447 ↗
3. 10.1681/ASN.202007110610.1681/ASN.2020071106 ↗
4. 10.7150/thno.3171110.7150/thno.31711 ↗
5. 10.1038/nature1443210.1038/nature14432 ↗
6. 10.1038/nrc318610.1038/nrc3186 ↗
7. 10.1038/s41580-020-00298-710.1038/s41580-020-00298-7 ↗
8. 10.1158/2326-6066.CIR-14-016110.1158/2326-6066.CIR-14-0161 ↗
9. 10.1182/blood-2015-06-65366710.1182/blood-2015-06-653667 ↗
10. 10.1182/blood-2017-11-78586510.1182/blood-2017-11-785865 ↗
11. 10.1172/JCI9059810.1172/JCI90598 ↗
12. 10.1038/s41423-019-0220-610.1038/s41423-019-0220-6 ↗
13. 10.1097/TP.000000000000137910.1097/TP.0000000000001379 ↗
14. 10.1002/JLB.3MR0420-533RR10.1002/JLB.3MR0420-533RR ↗
15. 10.1038/s41423-021-00764-y10.1038/s41423-021-00764-y ↗
16. 10.18632/oncotarget.692710.18632/oncotarget.6927 ↗
17. 10.1038/s41573-019-0041-410.1038/s41573-019-0041-4 ↗
18. 10.1126/scitranslmed.abb012210.1126/scitranslmed.abb0122 ↗
19. 10.3389/fimmu.2021.79626010.3389/fimmu.2021.796260 ↗
20. 10.1172/JCI8112910.1172/JCI81129 ↗
21. 10.1038/nrm.2017.12510.1038/nrm.2017.125 ↗
22. 10.1126/scitranslmed.aav852110.1126/scitranslmed.aav8521 ↗
23. 10.7150/thno.4786510.7150/thno.47865 ↗
24. 10.7150/thno.3709710.7150/thno.37097 ↗
25. 10.1016/j.ymben.2015.01.00810.1016/j.ymben.2015.01.008 ↗
26. 10.1016/j.cell.2017.10.03410.1016/j.cell.2017.10.034 ↗
27. 10.1038/s41467-018-03733-810.1038/s41467-018-03733-8 ↗
28. 10.1080/20013078.2020.180767410.1080/20013078.2020.1807674 ↗
29. 10.2174/138920101766616080816051310.2174/1389201017666160808160513 ↗
30. 10.1038/s41580-022-00460-310.1038/s41580-022-00460-3 ↗
31. 10.3390/cells904085110.3390/cells9040851 ↗
32. 10.1126/sciadv.aaz074810.1126/sciadv.aaz0748 ↗
33. 10.1016/j.kint.2021.10.03810.1016/j.kint.2021.10.038 ↗
34. 10.1186/gb-2007-8-5-21510.1186/gb-2007-8-5-215 ↗
35. 10.1097/00007890-197509000-0000610.1097/00007890-197509000-00006 ↗
36. 10.1084/jem.128.1.19710.1084/jem.128.1.197 ↗
37. 10.1016/0092-8674(88)90434-510.1016/0092-8674(88)90434-5 ↗
38. 10.1084/jem.171.1.30710.1084/jem.171.1.307 ↗
39. 10.1097/00000658-199009000-0000910.1097/00000658-199009000-00009 ↗
40. 10.1161/CIRCULATIONAHA.117.02853310.1161/CIRCULATIONAHA.117.028533 ↗
41. 10.1016/j.it.2011.11.00110.1016/j.it.2011.11.001 ↗
42. 10.1002/art.2340410.1002/art.23404 ↗
43. 10.3389/fimmu.2019.0034710.3389/fimmu.2019.00347 ↗
44. 10.1016/j.immuni.2020.11.00610.1016/j.immuni.2020.11.006 ↗
45. 10.2215/CJN.0070011710.2215/CJN.00700117 ↗
46. 10.1111/tri.1287310.1111/tri.12873 ↗
47. 10.1021/acsnano.9b0906510.1021/acsnano.9b09065 ↗
48. 10.1039/D0BM01798A10.1039/D0BM01798A ↗
49. 10.1097/MOT.000000000000015110.1097/MOT.0000000000000151 ↗
50. 10.1038/7496310.1038/74963 ↗
51. 10.2215/CJN.0990101410.2215/CJN.09901014 ↗
52. 10.1097/TP.0b013e318277b2e210.1097/TP.0b013e318277b2e2 ↗
53. 10.1016/j.trim.2008.03.00410.1016/j.trim.2008.03.004 ↗
54. 10.1182/blood-2008-02-14027710.1182/blood-2008-02-140277 ↗
55. 10.1681/ASN.201605057310.1681/ASN.2016050573 ↗
56. 10.1097/TP.0b013e318250c10f10.1097/TP.0b013e318250c10f ↗
57. 10.3389/fimmu.2022.82922810.3389/fimmu.2022.829228 ↗
58. 10.1111/j.1600-6143.2007.02006.x10.1111/j.1600-6143.2007.02006.x ↗
59. 10.1681/ASN.200809100510.1681/ASN.2008091005 ↗
60. 10.1038/ki.2012.27710.1038/ki.2012.277 ↗
61. 10.1002/micr.192016021210.1002/micr.1920160212 ↗
62. 10.1038/nm.226110.1038/nm.2261 ↗